Eisai and Biogen begin application process for second Alzheimer's drug
Lecanemab, which is being developed as a treatment for Alzheimer's disease by Eisai and Biogen, has been sent to the FDA through a "rolling submission" process under an accelerated approval pathway.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
Eisai and Biogen are now making another attempt to tackle Alzheimer's disease, initiating a "rolling submission" process at the US Food and Drug Administration (FDA) of the drug lecanemab, the companies inform in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biogen partner calls for global Alzheimer's effort
For subscribers
